Genu Recurvatum Global Market Report 2024

The genu recurvatum market size has grown strongly in recent years. It will grow from $7.12 billion in 2023 to $7.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historic period can be credited to factors such as the increased prevalence of orthopedic conditions, the aging demographic, incidents of trauma and accidents, as well as limited awareness and early diagnosis.

The genu recurvatum market size is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The projected growth in the forecast period can be linked to increasing awareness and educational efforts, advancements in diverse treatment options, emphasis on sports injury prevention and effective management, and the development of improved rehabilitation programs. Key trends anticipated in the forecast period involve the integration of digital health technologies, enhanced collaboration between orthopedic specialists and physical therapists, research focusing on biomechanics and musculoskeletal health, attention to pediatric and adolescent cases, and an increased emphasis on rehabilitation and strength training.

The increasing prevalence of orthopedic disorders is anticipated to drive the growth of the genu recurvatum market. Orthopedic disorders encompass various conditions affecting the musculoskeletal system, leading to complications in bones, joints, muscles, tendons, ligaments, and cartilage. Genu recurvatum, a condition causing knee pain and contributing to knee osteoarthritis, is among the orthopedic disorders requiring treatment. Notably, the Office of Disease Prevention and Health Promotion reported an expected rise in arthritis cases, with 78.4 million adults projected to have arthritis by 2040. In 2022, more than 22% of the adult American population, totaling 52.5 million individuals, already had arthritis. Additionally, Versus Arthritis noted 20,295,706 people with musculoskeletal conditions in the UK in 2021. The increasing prevalence of orthopedic disorders underscores the demand for genu recurvatum treatment, fueling market growth.

The growth of the genu recurvatum market is expected to be propelled by the rising aging population. This demographic shift involves an increasing proportion of elderly individuals within society. The treatment of genu recurvatum in the aging population aims to address underlying causes and improve functional outcomes. According to the World Health Organization's projections in October 2022, it is expected that by 2030, one out of every six individuals globally will be 60 years old or older. The proportion of the population aged 60 and over is anticipated to rise from 1 billion in 2020 to 1.4 billion by 2030. Furthermore, by 2050, the global population of individuals aged 60 and older is predicted to double, reaching 2.1 billion. This demographic shift toward an older population contributes to the growth of the genu recurvatum market.

Technological advancements emerge as a significant trend in the genu recurvatum market, with major companies focusing on developing advanced products to maintain their market positions. In November 2022, Ortho Development Corporation, a US-based orthopedic device design and manufacturing company, introduced BKS Total PSI in collaboration with Materialize NV, a Belgium-based company specializing in 3D printing and additive manufacturing. BKS Total PSI, driven by Materialize, enhances total knee arthroplasty predictability and control through patient-specific virtual visualization, preoperative planning, and precise 3D-printed guidance.

Companies in the genu recurvatum market are channeling their efforts into the development of innovative solutions such as microprocessor prosthetic knees. A microprocessor prosthetic knee integrates microprocessor technology into artificial knee joints, improving the functionality and performance of prosthetic limbs. In September 2022, Össur, an Iceland-based non-invasive orthopedic equipment manufacturing company, launched the 'POWER KNEE,' touted as the world's first actively powered microprocessor prosthetic knee for individuals with knee amputation or limb differences. This groundbreaking bionic technology incorporates a motor-powered 'smart' prosthesis equipped with advanced algorithms. It can detect human movement patterns, learn from them, and dynamically adjust to the wearer's speed and cadence in real-time.

In April 2023, NuVasive, Inc., a US-based medical device company, completed a merger with Globus Medical, Inc. This strategic union brought together two esteemed technological entities within the Musculoskeletal sector. The merger aimed to enhance innovation, broaden global medical and commercial outreach, and bolster support for a larger patient base. Globus Medical Inc., a US-based firm, specializes in developing, manufacturing, and distributing musculoskeletal device solutions, including revision knee replacements.

Major companies operating in the genu recurvatum market report are Medtronic plc, Johnson & Johnson MedTech,Stryker Corporation, DePuy Synthes Inc., Zimmer Inc., Smith & Nephew plc, Arthrex, NuVasive Inc., DJO Global Inc., Globus Medical Inc., Össur hf, AliMed Inc., Thuasne Ltd., Orthofix Inc, Prim SA, OrthoPro Inc., Performance Health, Trulife Group Limited, Breg Inc., Allard USA, Capstone Orthopedic Inc., Twin Cities Orthopedics, ReWalk Robotics, BraceAbility, KevinRoot Medical.

North America was the largest region in the genu recurvatum market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genu recurvatum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genu recurvatum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The various types of genu recurvatum include external rotatory deformity (ERD), internal rotatory deformity (IRD), and non-rotatory deformity (NRD). ERD specifically refers to a rotational deformity where the foot or leg bone is twisted outward. Diagnosis typically involves methods such as magnetic resonance imaging (MRI), x-rays, among others. Treatment options may include physical therapy, orthotic devices, bracing, or surgical intervention. The primary end users for addressing this condition include hospitals, clinics, and similar healthcare facilities.

The genu recurvatum market research report is one of a series of new reports that provides genu recurvatum market statistics, including genu recurvatum industry global market size, regional shares, competitors with a genu recurvatum market share, detailed genu recurvatum market segments, market trends and opportunities, and any further data you may need to thrive in the genu recurvatum industry. This genu recurvatum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genu recurvatum market includes of revenues earned by entities by providing services such as physiotherapy and strengthening of calf muscles. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.